

Kirk R Schultz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2395163/kirk-r-schultz-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179
papers

9,383
citations

43
h-index

95
g-index

192
ext. papers

11,120
ext. citations

3.6
avg, IF

5.21
L-index

#	Paper	IF	Citations
179	National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 945-56	4.7	2749
178	Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5175-81 ²	8.2	540
177	Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 31-47	4.7	357
176	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007 , 109, 926-35	2.2	338
175	Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. <i>Leukemia</i> , 2014 , 28, 1467-71	10.7	298
174	Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 266-74	4.7	214
173	One-unit versus two-unit cord-blood transplantation for hematologic cancers. <i>New England Journal of Medicine</i> , 2014 , 371, 1685-94	59.2	214
172	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 211-234	4.7	206
171	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology</i> , 2016 , 17, 164-173	21.7	199
170	Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 984-99	4.7	196
169	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014 , 124, 2596-606	2.2	184
168	NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 589-603	4.7	165
167	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015 , 125, 3501-8	2.2	135
166	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1167-87	4.7	128
165	Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 126-37	4.7	127
164	EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1401-1415	4.4	120
163	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2306-2314	2.2	119

162	Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. <i>Blood</i> , 2008 , 111, 3276-85	2.2	117
161	Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. <i>Blood</i> , 2016 , 127, 392-9	2.2	101
160	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010 , 116, 4007-15	2.2	94
159	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014 , 123, 2017-25	2.2	93
158	Combined immunodeficiency associated with homozygous MALT1 mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 1458-62, 1462.e1-7	11.5	91
157	A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. <i>British Journal of Haematology</i> , 1999 , 106, 1027-32	4.5	90
156	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 780-92	4.7	87
155	Chronic graft-versus-host disease (GVHD) in children. <i>Pediatric Clinics of North America</i> , 2010 , 57, 297-323.6	3.6	87
154	Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1995 , 16, 289-95	4.4	82
153	Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. <i>Medical and Pediatric Oncology</i> , 2000 , 35, 41-6		75
152	Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 386-97	4.7	71
151	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. <i>Leukemia</i> , 2018 , 32, 2316-2325	10.7	60
150	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016 , 127, 3082-91	2.2	57
149	Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 218-27	4.7	56
148	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> , 2018 , 132, 1438-1451	2.2	55
147	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 322-328.e10	11.5	53
146	The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 1997 , 24, 201-10	1.9	53
145	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3282-3293.2	3.2	51

144	Improved survival after acute graft–host disease diagnosis in the modern era. <i>Haematologica</i> , 2017 , 102, 958-966	6.6	50
143	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50
142	Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1029-36	4.7	49
141	TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 67-73	4.7	48
140	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019 , 3, 3393-3405	7.8	47
139	Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. <i>Blood</i> , 2014 , 123, 1615-20	2.2	46
138	Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1173-9	4.4	46
137	Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 84-91	4.7	44
136	Obstructive lung disease in children after allogeneic bone marrow transplantation: evaluation with high-resolution CT. <i>American Journal of Roentgenology</i> , 1995 , 164, 693-6	5.4	43
135	Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 624-34	4.7	42
134	An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India. <i>Cancer</i> , 1993 , 72, 282-6	6.4	40
133	Biomarkers in chronic graft-versus-host disease: quo vadis?. <i>Bone Marrow Transplantation</i> , 2018 , 53, 832-837	4.7	36
132	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019 , 37, 780-789	2.2	33
131	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e100-e111	14.6	32
130	Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. <i>Blood</i> , 2019 , 134, 304-316	2.2	31
129	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 932-40	4.7	30
128	Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, S115-22	4.7	30
127	Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1804-13	4.7	29

126	Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. <i>Medical and Pediatric Oncology</i> , 1997 , 29, 16-22		27
125	Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 26, 545-51	4.4	27
124	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 870-881	4.7	26
123	A population-based study of pediatric anaplastic large cell lymphoma. <i>Cancer</i> , 2002 , 94, 1830-5	6.4	26
122	Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation. <i>Clinical Immunology</i> , 2016 , 168, 1-5	9	25
121	Severe combined immunodeficiency (SCID) in Canadian children: a national surveillance study. <i>Journal of Clinical Immunology</i> , 2013 , 33, 1310-6	5.7	24
120	ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. <i>British Journal of Haematology</i> , 2002 , 116, 266-272	4.5	24
119	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27827	3	22
118	Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. <i>Leukemia</i> , 2014 , 28, 964-7	10.7	21
117	In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2173-2179	4.7	21
116	Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene. <i>Journal of Clinical Immunology</i> , 2015 , 35, 15-21	5.7	20
115	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2062-2076	2.2	19
114	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 521-528	4.7	19
113	Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 648-55	4.7	18
112	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1865-1877	2.2	18
111	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019 , 3, 3123-3131	7.8	18
110	Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. <i>Blood</i> , 2020 , 135, 1287-1298	2.2	18
109	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2040-2046	4.7	18

108	Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length. <i>Pediatric Hematology and Oncology</i> , 2018 , 35, 45-51	1.7	17
107	New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1259-65	4.4	17
106	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1714-1721	4.7	17
105	Biomarkers in chronic graft-versus-host disease. <i>Expert Review of Hematology</i> , 2011 , 4, 329-42	2.8	17
104	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). <i>Blood</i> , 2017 , 130, 98-98	2.2	17
103	Obstructive lung disease in children after allogeneic bone marrow transplantation. <i>Blood</i> , 1994 , 84, 3212-20	2.0	16
102	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2014 , 124, 795-795	2.2	16
101	Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1410-1417	4.7	16
100	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 545-557		15
99	Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. <i>Blood</i> , 2014 , 124, 38-38	2.2	14
98	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 270-278	4.7	14
97	CD56 natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. <i>Haematologica</i> , 2017 , 102, 1936-1946	6.6	13
96	Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia. <i>Pediatric Hematology and Oncology</i> , 2011 , 28, 469-78	1.7	13
95	Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A. <i>Journal of Pediatrics</i> , 1997 , 130, 467-70	3.6	13
94	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2016 , 101, 1267-1274	6.6	13
93	Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2017 , 4, 2054358117690338	2.3	11
92	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020 , 189, 363-368	4.5	11
91	Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. <i>Expert Review of Hematology</i> , 2010 , 3, 731-42	2.8	11

90	Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. <i>Bone Marrow Transplantation</i> , 1996 , 18, 625-31	4.4	11
89	Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. <i>JAMA Network Open</i> , 2020 , 3, e203639	10.4	10
88	Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia. <i>European Journal of Immunology</i> , 2015 , 45, 1980-90	6.1	10
87	The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation. <i>Transplantation Proceedings</i> , 1998 , 30, 1668-70	1.1	10
86	Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias. <i>Medical and Pediatric Oncology</i> , 2001 , 37, 415-6		10
85	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 451-458	4.7	10
84	Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27431	3	10
83	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020 , 105, 1329-1338	6.6	9
82	HLA-DM expression is elevated in ETV6-AML1 translocation-positive pediatric acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2006 , 30, 487-9	2.7	9
81	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. <i>Blood</i> , 2012 , 120, 359-359	2.2	9
80	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). <i>Blood</i> , 2013 , 122, 543-543	2.2	9
79	Plerixafor effectively mobilizes CD56 NK cells in blood, providing an allograft predicted to protect against GVHD. <i>Blood</i> , 2018 , 131, 2863-2866	2.2	9
78	Will post-transplantation cell therapies for pediatric patients become standard of care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 402-11	4.7	8
77	The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation. <i>Experimental Hematology</i> , 2019 , 70, 1-9	3.1	8
76	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018 , 2, 1022-1031	7.8	8
75	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1875-1883	4.7	7
74	Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignancies. <i>Pediatric Clinics of North America</i> , 2015 , 62, 257-73	3.6	7
73	Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. <i>Blood</i> , 1995 , 86, 4344-52	2.2	7

72	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 472-479	4-7	7
71	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 452-466		7
70	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019 , 3, 1441-1449	7.8	7
69	The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. <i>Pediatric Hematology and Oncology</i> , 2019 , 36, 468-481	1.7	6
68	Functional hyposplenism after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1343-7	4.4	6
67	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1790-5	4.7	6
66	Pathophysiology of Chronic Graft versus Host Disease17-30		6
65	How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28543	3	6
64	Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 321-327	4.7	6
63	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 632-641		6
62	Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1263-1269	4.4	5
61	STAT3 mutations and persistence of autoimmunity. <i>Blood</i> , 2013 , 122, 2295-6	2.2	5
60	Misleading leads: Bone pain caused by isolated paraspinal extramedullary relapse of childhood acute lymphoblastic leukemia. <i>Medical and Pediatric Oncology</i> , 1999 , 33, 113-5		5
59	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 553-561	4.7	5
58	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021 , 41, 38-50	5.7	5
57	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021 , 137, 983-993	2.2	5
56	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 729-737		5
55	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 817-835		5

54	Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2017 , 13, 497-505	2.6	4
53	Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1653-7	4.4	4
52	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012 , 120, 137-137	2.2	4
51	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015 , 126, 807-807	2.2	4
50	Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky079	4.6	4
49	Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1172-1178	4.7	3
48	Acute T-Cell Leukemias Remain Dependent On Notch Signaling Despite PTEN and INK4A/ARF Loss.. <i>Blood</i> , 2009 , 114, 8-8	2.2	3
47	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. <i>Blood</i> , 2012 , 120, 172-172	2.2	3
46	A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 709-709	2.2	3
45	Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study. <i>Blood</i> , 2013 , 122, 919-919	2.2	3
44	Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	3
43	"Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation". <i>Frontiers in Immunology</i> , 2020 , 11, 571884	8.4	3
42	Quantitation of Human Cells that Produce Neutrophils and Platelets in Vivo Obtained from Normal Donors Treated with Granulocyte Colony-Stimulating Factor and/or Plerixafor. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1945-1952	4.7	3
41	Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study. <i>Pediatric Hematology and Oncology</i> , 2018 , 35, 288-296	1.7	3
40	Is any donor too old?. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2-3	4.7	2
39	Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).. <i>Blood</i> , 2004 , 104, 519-519	2.2	2
38	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28574	3	2
37	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1928-1935	4.7	1

36	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2008 , 112, 911-911	2.2	1
35	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. <i>Blood</i> , 2011 , 118, 837-837	2.2	1
34	Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation. <i>Blood</i> , 2014 , 124, 2489-2489	2.2	1
33	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. <i>Blood</i> , 2016 , 128, 1231-1231	2.2	1
32	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021 , 138, 3880-3880	2.2	1
31	An Exaggerated B Cell CpG Response in Human Chronic Graft-versus-Host Disease: A Potential Mechanism and Biomarker for Diagnosis of Chronic GVHD.. <i>Blood</i> , 2004 , 104, 4966-4966	2.2	1
30	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides.. <i>Blood</i> , 2006 , 108, 1868-1868	2.2	1
29	Heterodimer-Specific Stimulation Of Toll-Like Receptor 2 Induces Divergent Downstream Effects In Primary Samples Of Precursor B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 3918-3918	2.2	1
28	Anti-Thymocyte Globulin Prophylaxis Induces a Decrease in Naive Th Cells to Inhibit the Onset of Chronic Graft-versus-Host Disease: Results from the Canadian Bone Marrow Transplant Group (CBMTG) 0801 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 438-444	4.7	1
27	Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2193-2201	1.9	1
26	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2108-2117	4.4	1
25	Regional differences in access to hematopoietic stem cell transplantation among pediatric patients with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28263	3	0
24	Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTG 1202 Study. <i>Blood</i> , 2020 , 136, 11-12	2.2	0
23	Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.. <i>Kidney360</i> , 2022 , 3, 37-50	1.8	0
22	Successful rescue transplant for children with primary graft failure using early intervention with a single day preparative regimen and related haploidentical donor. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2031-2033	4.4	0
21	Too stressed for tests? Challenges of diagnosing psychological distress in pediatric cancer patients and survivors. <i>Pediatric Hematology and Oncology</i> , 2019 , 36, 123-124	1.7	
20	Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia 2022 , 405-430		
19	What Is the Role of HSCT in Philadelphia-Chromosome-Positive and Philadelphia-Chromosome-Like ALL in the Tyrosine Kinase Inhibitor Era?. <i>Frontiers in Pediatrics</i> , 2021 , 9, 807002	3.4	

18	Detection of T-Cells Specific for Leukemia-Associated Antigens in Pediatric Patients with Acute Lymphoblastic Leukemia in First Complete Remission.. <i>Blood</i> , 2004 , 104, 526-526	2.2
17	Chronic Graft-Versus-Host Disease after Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplantation. A Pediatric Blood and Marrow Transplant Consortium Study... <i>Blood</i> , 2007 , 110, 4984-4984	2.2
16	Provincial Disparities in Access to Allogeneic Transplant in Canada. <i>Blood</i> , 2018 , 132, 4742-4742	2.2
15	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018 , 132, 659-659	2.2
14	Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial. <i>Blood</i> , 2019 , 134, 875-875	2.2
13	Prior Granulocyte Colony-Stimulating Factor Treatment Enhances the Immediate and Transient Output of Primitive Hematopoietic Cells in the Blood of Normal Adult Human Donors Treated with Plerixafor. <i>Blood</i> , 2014 , 124, 5787-5787	2.2
12	Impact of Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplant for Children with AML beyond the First Complete Remission: Total Body Irradiation Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTc) Study. <i>Blood</i> , 2008 , 112, 3006-3006	2.2
11	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031. <i>Blood</i> , 2009 , 114, 2634-2634	2.2
10	Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. <i>Blood</i> , 2009 , 114, 2634-2634	2.2
9	The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation.. <i>Blood</i> , 2009 , 114, 2280-2280	2.2
8	Therapeutic Potential for Toll-Like Receptor 2 Agonists In Pediatric Acute Lymphoblastic Leukemia (pre-B ALL): Induction of Apoptosis and Anti-ALL Immunogenicity. <i>Blood</i> , 2010 , 116, 870-870	2.2
7	Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes. <i>Blood</i> , 2012 , 120, 467-467	2.2
6	Functional Hyposplenism in Pediatric Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2012 , 120, 4493-4493	2.2
5	YB-1 Is Activated by IL-7 and Is Overexpressed in Pediatric Pre-B Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 1468-1468	2.2
4	Higher Proportions of IFNg-Producing T Cells, CD56bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial. <i>Blood</i> , 2012 , 120, 1944-1944	2.2
3	Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?. <i>Pediatric Hematology and Oncology</i> , 2021 , 38, 417-419	1.7
2	Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?. <i>Frontiers in Pediatrics</i> , 2022 , 10, 796994	3.4
1	236 Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. <i>Journal of Clinical and Translational Science</i> , 2022 , 6, 37-38	0.4

